Featured Research

from universities, journals, and other organizations

Actos for diabetes? Medical societies respond to the FDA's safety announcement on the use of Actos

Date:
June 16, 2011
Source:
The Endocrine Society
Summary:
Experts urge diabetes patients to remain on their prescribed medications unless instructed otherwise by their health-care provider.

The Endocrine Society, American Association of Clinical Endocrinologists and American Diabetes Association urge diabetes patients to remain on their prescribed medications unless instructed otherwise by their health-care provider.

Diabetes leaders are responding to the announcement made by the U.S. Food and Drug Administration (FDA) on June 16 that the use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. According to the FDA's Safety Announcement, information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.

In response to this important safety announcement from the FDA, The Endocrine Society, the American Association of Clinical Endocrinologists and the American Diabetes Association urge patients who are currently taking Actos or any combination of medication that includes pioglitazone, to continue taking all currently prescribed medications unless instructed otherwise by their healthcare provider. Stopping diabetes medications can result in higher levels of blood glucose that may cause serious short term health problems and could increase the risk of diabetes-related complications in the long term.

The Endocrine Society, American Association of Clinical Endocrinologists and American Diabetes Association recommend that patients adhere to the following guidance provided by the FDA:

  • There may be an increased chance of having bladder cancer when taking pioglitazone;
  • Do not take pioglitazone if receiving treatment for bladder cancer;
  • Talk to your doctor right away if you have any of the symptoms of bladder cancer including blood or red color in urine; urgent need to urinate or pain while urinating; pain in back or lower abdomen;
  • Read the Medication Guide included with pioglitazone medicine as it explains risks associated with the use of the drug; and
  • Talk to your healthcare professional if you have questions of concerns about pioglitazone medicines.

According to the FDA Safety Announcement, the five-year interim analysis of an ongoing ten-year study showed that although there was no overall increased risk of bladder cancer with pioglitazone use, an increased risk of bladder cancer was noted among patients who had been on pioglitazone the longest and had been on higher doses over time.

The Endocrine Society, the American Association of Clinical Endocrinologists and the American Diabetes Association continue to support the FDA in its role as the regulatory agency that makes decisions regarding drug safety and efficacy.


Story Source:

The above story is based on materials provided by The Endocrine Society. Note: Materials may be edited for content and length.


Cite This Page:

The Endocrine Society. "Actos for diabetes? Medical societies respond to the FDA's safety announcement on the use of Actos." ScienceDaily. ScienceDaily, 16 June 2011. <www.sciencedaily.com/releases/2011/06/110616193903.htm>.
The Endocrine Society. (2011, June 16). Actos for diabetes? Medical societies respond to the FDA's safety announcement on the use of Actos. ScienceDaily. Retrieved July 30, 2014 from www.sciencedaily.com/releases/2011/06/110616193903.htm
The Endocrine Society. "Actos for diabetes? Medical societies respond to the FDA's safety announcement on the use of Actos." ScienceDaily. www.sciencedaily.com/releases/2011/06/110616193903.htm (accessed July 30, 2014).

Share This




More Health & Medicine News

Wednesday, July 30, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
Generics Eat Into Pfizer's Sales

Generics Eat Into Pfizer's Sales

Reuters - Business Video Online (July 29, 2014) Pfizer, the world's largest drug maker, cut full-year revenue forecasts because generics could cut into sales of its anti-arthritis drug, Celebrex. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Nigeria Ups Ebola Stakes on 1st Death

Nigeria Ups Ebola Stakes on 1st Death

Reuters - Business Video Online (July 29, 2014) Nigerian authorities have shut and quarantined a Lagos hospital where a Liberian man died of the Ebola virus, the first recorded case of the highly-infectious disease in Africa's most populous economy. David Pollard reports Video provided by Reuters
Powered by NewsLook.com
Running 5 Minutes A Day Might Add Years To Your Life

Running 5 Minutes A Day Might Add Years To Your Life

Newsy (July 29, 2014) According to a new study, just five minutes of running or jogging a day could add years to your life. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins